We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+42.82%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$417M
AUM Growth
+$95.9M
Cap. Flow
-$11.1M
Cap. Flow %
-2.67%
Top 10 Hldgs %
49.63%
Holding
82
New
7
Increased
14
Reduced
24
Closed
6

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$4.86M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$4.37M
3
BHVN icon
Biohaven
BHVN
+$4.16M
4
SLRN
ACELYRIN
SLRN
+$3.11M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$2.58M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$8.98M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.02M
3
NRIX icon
Nurix Therapeutics
NRIX
+$4.38M
4
CYTK icon
Cytokinetics
CYTK
+$2.88M
5
AUTL
Autolus Therapeutics
AUTL
+$2.81M

Sector Composition

Rank Sector Weight
1 Healthcare 85.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACET icon
76
Adicet Bio
ACET
$76.4M
– –
-49,816
Closed -$1.09M
MRSN
77
DELISTED
Mersana Therapeutics
MRSN
– –
-29,362
Closed -$932K
NRIX icon
78
Nurix Therapeutics
NRIX
$2.64B
– –
-556,695
Closed -$4.38M
NXTC icon
79
NextCure
NXTC
$21.9M
– –
-13,849
Closed -$214K
THRD
80
DELISTED
Third Harmonic Bio
THRD
– –
-300,000
Closed -$1.92M
CERE
81
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-62,200
Closed -$1.36M
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return

DAFNA Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, DAFNA Capital Management held 82 positions worth $417M, up 30% from $321M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

DAFNA Capital Management's Q4 2023 filing shows 7 new, 14 increased, 24 reduced and 6 closed positions. Its largest new stake was Sage Therapeutics: 245,000 shares worth $5.31M. The largest sale was Blueprint Medicines, an estimated $8.98M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 82% a quarter earlier.

  • DAFNA Capital Management's largest Q4 2023 buy was Sage Therapeutics: 245,000 shares worth $5.31M.
  • DAFNA Capital Management added most to Syndax Pharmaceuticals in Q4 2023, an estimated $4.37M increase.
  • DAFNA Capital Management's biggest Q4 2023 reduction was Blueprint Medicines, cutting an estimated $8.98M.
  • DAFNA Capital Management fully exited Nurix Therapeutics in Q4 2023, selling an estimated $4.38M.
  • DAFNA Capital Management's ten largest holdings make up 50% of its $417M portfolio in Q4 2023.
  • DAFNA Capital Management opened 7 new positions and closed 6 in Q4 2023.
  • DAFNA Capital Management's portfolio value rose 30% quarter-over-quarter to $417M.

Based on DAFNA Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.